CDIO: AI 评分 42/100 — AI 分析 (4月 2026)

Cardio Diagnostics Holdings, Inc. focuses on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. Its primary product is Epi+Gen CHD, a three-year risk assessment test for symptomatic coronary heart disease.

Key Facts: AI Score: 42/100 Sector: Healthcare

公司概况

概要：

Cardio Diagnostics Holdings, Inc. is a biotechnology company specializing in epigenetics-based clinical tests for cardiovascular disease, primarily offering the Epi+Gen CHD risk assessment test. The company operates within the competitive healthcare sector, focusing on innovative diagnostic solutions for personalized medicine.

CDIO是做什么的？

Cardio Diagnostics Holdings, Inc., founded in 2017 and based in Chicago, Illinois, is a biotechnology company focused on developing and commercializing innovative, epigenetics-based clinical tests for cardiovascular disease. The company's primary offering is Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. This test utilizes a patient's epigenetic and genetic markers to provide a personalized risk assessment, aiding physicians in making more informed decisions about patient care. Cardio Diagnostics aims to improve the accuracy and efficiency of cardiovascular disease diagnosis and management through its proprietary technology. By focusing on epigenetics, the company seeks to identify risk factors that may not be apparent through traditional diagnostic methods. The company is relatively small, with 13 employees, reflecting its stage as an emerging player in the biotechnology sector. The company's focus on epigenetics places it within a growing area of personalized medicine, with the potential to expand its product offerings and market reach as it further develops its technology and establishes partnerships with healthcare providers.

CDIO的投资论点是什么？

Cardio Diagnostics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on epigenetics-based cardiovascular disease diagnostics offers potential for significant growth, driven by the increasing demand for personalized medicine and early disease detection. However, the company's negative profit margin of -43832.5% and gross margin of -2180.2% indicate significant financial challenges. The company's success hinges on the successful commercialization and adoption of its Epi+Gen CHD test. Upcoming catalysts include potential partnerships with healthcare providers and expansion of its product line. Potential risks include competition from established diagnostic companies, regulatory hurdles, and the need for additional funding to support operations and growth.

CDIO在哪个行业运营？

Cardio Diagnostics Holdings, Inc. operates within the biotechnology industry, specifically focusing on cardiovascular disease diagnostics. The market for cardiovascular diagnostics is driven by the increasing prevalence of heart disease and the growing demand for early and accurate detection methods. The company's epigenetics-based approach positions it within the personalized medicine segment, which is experiencing rapid growth. Competitors include companies like ADIL, ADXN, BCDA, BCLI, and CELZ, which offer various diagnostic solutions. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements.

Biotechnology

Healthcare

CDIO有哪些增长机遇？

Expansion of Product Line: Cardio Diagnostics has the opportunity to develop and commercialize additional epigenetics-based diagnostic tests for other cardiovascular conditions. This could include tests for heart failure, stroke risk, and other related diseases. The market for cardiovascular diagnostics is estimated to reach $25 billion by 2028, providing a significant opportunity for growth. Timeline: 2-3 years.
Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician practices to integrate Epi+Gen CHD into their diagnostic protocols can drive adoption and increase revenue. Strategic partnerships can provide access to a wider patient base and enhance the company's credibility. Timeline: Ongoing.
Geographic Expansion: Expanding into new geographic markets, both domestically and internationally, can significantly increase the company's market reach. This could involve targeting regions with high prevalence of cardiovascular disease and unmet diagnostic needs. Timeline: 3-5 years.
Development of Companion Diagnostics: Developing companion diagnostics that can be used to identify patients who are most likely to benefit from specific cardiovascular therapies can create a valuable niche market. This requires collaboration with pharmaceutical companies and a deep understanding of drug development. Timeline: 4-6 years.
Direct-to-Consumer Testing: Offering Epi+Gen CHD directly to consumers through online platforms and partnerships with telehealth providers can expand access to the test and increase awareness. This requires careful consideration of regulatory requirements and ethical considerations. Timeline: 2-3 years.

Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
P/E ratio of -0.79 reflects the company's current lack of profitability.
Profit margin of -43832.5% highlights the company's significant expenses relative to its revenue.
Gross margin of -2180.2% indicates that the cost of goods sold exceeds revenue, suggesting potential issues with pricing or production costs.
Beta of 2.23 suggests the stock is more volatile than the market, indicating higher risk and potential reward.

CDIO提供哪些产品和服务？

Develops epigenetics-based clinical tests for cardiovascular disease.
Commercializes diagnostic tests for risk assessment.
Offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.
Utilizes epigenetic and genetic markers for personalized risk assessment.
Aids physicians in making informed decisions about patient care.
Focuses on improving the accuracy and efficiency of cardiovascular disease diagnosis.

CDIO如何赚钱？

Develops and commercializes epigenetics-based clinical tests.
Generates revenue through the sale of Epi+Gen CHD tests to healthcare providers and potentially direct-to-consumers.
Focuses on personalized medicine and early disease detection.

Hospitals and clinics
Physician practices
Potentially direct-to-consumers through online platforms and telehealth providers

Proprietary epigenetics-based technology
Focus on personalized medicine
Early mover advantage in the epigenetics-based cardiovascular diagnostics market

什么因素可能推动CDIO股价上涨？

Upcoming: Potential partnerships with healthcare providers to integrate Epi+Gen CHD into diagnostic protocols.
Upcoming: Expansion of the product line to include additional epigenetics-based diagnostic tests for other cardiovascular conditions.
Ongoing: Continued commercialization and adoption of Epi+Gen CHD test.
Ongoing: Research and development efforts to further enhance the company's epigenetics-based technology.

CDIO的主要风险是什么？

Potential: Competition from established diagnostic companies with greater financial and marketing resources.
Potential: Regulatory hurdles and the need for FDA approval for new diagnostic tests.
Ongoing: Need for additional funding to support operations and growth.
Potential: Technological obsolescence and the emergence of new diagnostic technologies.
Ongoing: The company's current financial performance, including negative profit and gross margins, poses a significant risk to its long-term viability.

CDIO的核心优势是什么？

Innovative epigenetics-based technology
Focus on personalized medicine
Potential for early disease detection
Proprietary Epi+Gen CHD test

CDIO的劣势是什么？

Negative profit margin
Negative gross margin
Limited financial resources
Small number of employees

CDIO有哪些机遇？

Expansion of product line
Partnerships with healthcare providers
Geographic expansion
Development of companion diagnostics

CDIO面临哪些威胁？

Competition from established diagnostic companies
Regulatory hurdles
Need for additional funding
Technological obsolescence

CDIO的竞争对手是谁？

Adial Pharmaceuticals, Inc. — Focuses on developing therapies for addiction. — (ADIL)
Addex Therapeutics Ltd — Develops small molecule allosteric modulators. — (ADXN)
Biocardia, Inc. — Develops cell therapies for cardiovascular diseases. — (BCDA)
Brainstorm Cell Therapeutics Inc. — Develops cell therapies for neurodegenerative diseases. — (BCLI)
Creative Medical Technology Holdings, Inc. — Develops regenerative medicine therapies. — (CELZ)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Meeshanthini V. Dogan
Headquarters: Chicago, US
Employees: 13
Founded: 2022

AI Insight

AI analysis pending for CDIO

常见问题

What does Cardio Diagnostics Holdings, Inc. do?

Cardio Diagnostics Holdings, Inc. is a biotechnology company that develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its primary product is Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. The company utilizes a patient's epigenetic and genetic markers to provide a personalized risk assessment, aiding physicians in making more informed decisions about patient care. Cardio Diagnostics aims to improve the accuracy and efficiency of cardiovascular disease diagnosis and management through its proprietary technology, focusing on epigenetics to identify risk factors that may not be apparent through traditional diagnostic methods.

What do analysts say about CDIO stock?

As of 2026-03-15, there is no available AI analyst consensus on Cardio Diagnostics Holdings, Inc. (CDIO). Given the company's micro-cap status and focus on epigenetics-based diagnostics, valuation metrics may be highly speculative. the may be worth researching company's growth potential in the context of its financial challenges, including negative profit and gross margins. Further research is needed to assess the long-term viability and potential returns of CDIO stock. The company's success hinges on the successful commercialization and adoption of its Epi+Gen CHD test.

What are the main risks for CDIO?

The main risks for Cardio Diagnostics Holdings, Inc. include intense competition from established diagnostic companies, regulatory hurdles associated with FDA approval for new tests, and the need for additional funding to support operations and growth. The company's current financial performance, characterized by negative profit and gross margins, poses a significant risk to its long-term viability. Additionally, the rapid pace of technological advancements in the biotechnology industry could lead to technological obsolescence. Investors should carefully consider these risks before investing in CDIO.